

# Winston Pharmaceuticals, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

https://marketpublishers.com/r/WE3459119BDBEN.html

Date: May 2025 Pages: 50 Price: US\$ 499.00 (Single User License) ID: WE3459119BDBEN

## **Abstracts**

Winston Pharmaceuticals, Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Winston Pharmaceuticals, Inc. and its competitors. This provides our Clients with a clear understanding of Winston Pharmaceuticals, Inc. position in the <u>Pharmaceuticals</u> and <u>Biotechnology</u> Industry.

The report contains detailed information about Winston Pharmaceuticals, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for Winston Pharmaceuticals, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The Winston Pharmaceuticals, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios



pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes Winston Pharmaceuticals, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Winston Pharmaceuticals, Inc. business.

### About Winston Pharmaceuticals, Inc.

Winston Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the discovery, development, and commercialization of products for pain management.

The company's proprietary technology affects the functioning of certain neurotransmitters that control and mediate pain transmission. Based on this technology, the company is in the process of developing products that reduce pain transmission from peripheral receptors along nerve pathways to the brain. The company focuses on pain indications, such as neuropathic pain syndromes, chronic daily headache, migraine headache, and osteoarthritis.

## Winston Product Pipeline

The company has developed multiple proprietary formulations and uses of civamide and doxepin hydrochloride, two agents that affect a variety of neuroactive chemical transmitters that convey primary sensory input from the periphery to the central nervous system.

Civamide: Civamide, a synthetically produced, proprietary new chemical entity, is the



active ingredient in the company's product candidates. Civamide produces analgesia by decreasing the activity of sensory neurons. Civamide appears to affect preferentially type-C neurons by specific binding to a membrane receptor, the TRPV-1 receptor, which is coupled to an action channel.

Civamide has also been shown to inhibit the synthesis of SP and reduce axonal transport of granules containing SP from the cell body to the nerve terminals. The company has preclinical and clinical experience with Civamide.

Civamide Patch: In 2009, the company completed Study WL-1001-04-03, a Phase II clinical trial evaluating the efficacy and safety of Civamide Patch 0.015% in the treatment of PHN.

Civamide Nasal Spray: The company completed a Phase II as well two Phase III clinical trials.

Civamide Cream: The company licensed the marketing rights for Civamide Cream to Sanofi-Aventis in Canada.

## Doxepin

The company is also developing doxepin hydrochloride, a potent histamine receptor blocker and serotonin reuptake inhibitor in a patented nasal solution formulation in a concentration of 0.4%, for the prophylaxis and treatment of chronic daily headache. The company completed a Phase IIa trial of Doxepin Nasal Spray in chronic daily headache.

### Other Products

Civamide Capsule: Civamide Capsules are being developed for the treatment of Crohn's disease. Crohn's disease is an inflammatory disease of the intestines that may affect any part of the gastrointestinal tract from anus to mouth, causing various symptoms. It primarily causes abdominal pain, diarrhea (which may be bloody), vomiting, or weight loss, but may also cause complications outside of the gastrointestinal tract, such as skin rashes, arthritis, and inflammation of the eye.

Civamide Nasal Spray: Civamide Nasal Spray in a concentration of 0.01%, is also being developed for the treatment of keratoconjuctivitis sicca, also known as dry eye syndrome, in addition to its development for the prophylaxis and treatment of Episodic Cluster Headache.



### Suppliers

The company's primary suppliers of contract manufacturing services are DPT Laboratories, Ltd., Patheon, Inc., Catalant Pharma Solutions, and Aveva Drug Delivery Systems. In particular, Civamide is manufactured for the company by Sigma-Aldrich Fine Chemicals.

## Competition

The company's primary competitors include small companies focused on pain management, such as Adolor, NeurogesX, NicOx, Pain Therapeutics, and Pozen; midsized companies with significant pain franchises, such as Endo Pharmaceuticals, King Pharmaceuticals, Purdue Pharma, and Valeant Pharmaceuticals; and very large, diversified pharmaceutical companies, including GlaxoSmithKline, Merck, and Pfizer.

## History

Winston Pharmaceuticals, Inc. was founded in 1992.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.



## Contents

## RESEARCH METHODOLOGY

DISCLAIMER

## 1. WINSTON PHARMACEUTICALS, INC. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

## 2. WINSTON PHARMACEUTICALS, INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

## 3. WINSTON PHARMACEUTICALS, INC. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

### 4. WINSTON PHARMACEUTICALS, INC. FINANCIAL ANALYSIS

- 4.1. Financial Statements
- 4.1.1. Income Statement
- 4.1.2. Balance Sheet
- 4.1.3. Cash Flow
- 4.2. Financial Ratios
- 4.2.1. Profitability
- 4.2.2. Margin Analysis



- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

## 5. WINSTON PHARMACEUTICALS, INC. COMPETITORS AND INDUSTRY ANALYSIS

- 5.1. Winston Pharmaceuticals, Inc. Direct Competitors
- 5.2. Comparison of Winston Pharmaceuticals, Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of Winston Pharmaceuticals, Inc. and Direct Competitors Stock Charts
- 5.4. Winston Pharmaceuticals, Inc. Industry Analysis
- 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
- 5.4.2. Winston Pharmaceuticals, Inc. Industry Position Analysis

## 6. WINSTON PHARMACEUTICALS, INC. NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

## 7. WINSTON PHARMACEUTICALS, INC. EXPERTS REVIEW<sup>1</sup>

- 7.1. Experts Consensus
- 7.2. Experts Revisions

## 8. WINSTON PHARMACEUTICALS, INC. ENHANCED SWOT ANALYSIS<sup>2</sup>

## 9. UNITED STATES PESTEL ANALYSIS<sup>2</sup>

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors



#### 9.6. Legal Factors

### 10. WINSTON PHARMACEUTICALS, INC. IFE, EFE, IE MATRICES<sup>2</sup>

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

## 11. WINSTON PHARMACEUTICALS, INC. PORTER FIVE FORCES ANALYSIS<sup>2</sup>

12. WINSTON PHARMACEUTICALS, INC. VRIO ANALYSIS<sup>2</sup>

### **APPENDIX: RATIO DEFINITIONS**

### LIST OF FIGURES

Winston Pharmaceuticals, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit Profit Margin Chart Operating Margin Chart Return on Equity (ROE) Chart Return on Assets (ROA) Chart Debt to Equity Chart Current Ratio Chart Winston Pharmaceuticals, Inc. 1-year Stock Charts Winston Pharmaceuticals, Inc. 5-year Stock Charts Winston Pharmaceuticals, Inc. vs. Main Indexes 1-year Stock Chart Winston Pharmaceuticals, Inc. vs. Direct Competitors 1-year Stock Charts Winston Pharmaceuticals, Inc. Article Density Chart

<sup>1 –</sup> Data availability depends on company's security policy.

<sup>2 –</sup> These sections are available only when you purchase a report with appropriate additional types of analyses. The complete financial data is available for publicly traded companies.



## **List Of Tables**

## LIST OF TABLES

Winston Pharmaceuticals, Inc. Key Facts Profitability Management Effectiveness Income Statement Key Figures **Balance Sheet Key Figures Cash Flow Statement Key Figures Financial Performance Abbreviation Guide** Winston Pharmaceuticals, Inc. Key Executives Winston Pharmaceuticals, Inc. Major Shareholders Winston Pharmaceuticals, Inc. History Winston Pharmaceuticals, Inc. Products Revenues by Segment Revenues by Region Winston Pharmaceuticals, Inc. Offices and Representations Winston Pharmaceuticals, Inc. SWOT Analysis Yearly Income Statement Including Trends Income Statement Latest 4 Quarters Including Trends Yearly Balance Sheet Including Trends Balance Sheet Latest 4 Quarters Including Trends Yearly Cash Flow Including Trends Cash Flow Latest 4 Quarters Including Trends Winston Pharmaceuticals, Inc. Profitability Ratios Margin Analysis Ratios Asset Turnover Ratios **Credit Ratios** Long-Term Solvency Ratios Financial Ratios Growth Over Prior Year Winston Pharmaceuticals, Inc. Capital Market Snapshot Winston Pharmaceuticals, Inc. Direct Competitors Key Facts **Direct Competitors Profitability Ratios Direct Competitors Margin Analysis Ratios Direct Competitors Asset Turnover Ratios Direct Competitors Credit Ratios Direct Competitors Long-Term Solvency Ratios** Pharmaceuticals and Biotechnology Industry Statistics



Winston Pharmaceuticals, Inc. Industry Position Company vs. Industry Income Statement Analysis Company vs. Industry Balance Sheet Analysis Company vs. Industry Cash Flow Analysis Company vs. Industry Ratios Comparison Winston Pharmaceuticals, Inc. Consensus Recommendations<sup>1</sup> Analyst Recommendation Summary<sup>1</sup> Price Target Summary<sup>1</sup> Experts Recommendation Trends<sup>1</sup> Revenue Estimates Analysis<sup>1</sup> Earnings Estimates Analysis<sup>1</sup> Historical Surprises<sup>1</sup> Revenue Estimates Trend<sup>1</sup> Earnings Estimates Trend<sup>1</sup> Earnings Estimates Trend<sup>1</sup> Revenue Revisions<sup>1</sup>



## **ANALYSIS FEATURES**

### **SWOT Analysis**

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

### **Enhanced SWOT Analysis**

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

### **PESTEL Analysis**

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.



Key Factors Examined by PESTEL Analysis:

Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

Sociological – What cultural and societal aspects will work upon the demand for the business's products and operations?

Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

Legal – What laws and legislation will exert influence on the style the business is carried out?

## IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors



integrated into one suggestive model.

#### **Porter Five Forces Analysis**

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

#### **VRIO** Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources Financial

Physical

Technological

Organizational

Intangible resources Human

Innovation and Creativity



Reputation

Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?

Rare?

Costly to imitate?

Organized properly?



## I would like to order

Product name: Winston Pharmaceuticals, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Product link: https://marketpublishers.com/r/WE3459119BDBEN.html

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

<u>inio@marketpublishers.</u>

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/WE3459119BDBEN.html</u>